RayzeBio has additional programs for hepatocellular carcinoma. Between $20 million and $25 million is set aside for RYZ801 and RYZ811, advancing both programs in this type of liver cancer through ...

Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less ...

RayzeBio's stock has fallen near its original IPO price, presenting an attractive buying opportunity. RYZB's lead drug in Phase-3 clinical testing has best-in-class potential for the treatment of ...

RayzeBio thinks its Ac225 RPT is the next generation in RPT development. The company thinks there are 7000 target patients per year. Rival drug price median is a quarter million dollars.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of ...

RayzeBio's $4.1 billion deal to be acquired by Bristol Myers caps a brief but lucrative run as a public company for the radiopharmaceutical firm. RayzeBio went public in September at $18 a share ...

Drug company Bristol-Myers Squibb BMY 0.26 % increase; green up pointing triangle struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology.

RayzeBio has just revealed it overshot expectations by raising $311 million, while Neumora Therapeutics was squarely on target with a $250 million offering. RayzeBio scores $311M oversized IPO ...

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show. The companies ...

Rayzebio, Inc. SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor ...

RayzeBio, started four years earlier, had gone public only a few months before the pharma giant swept in and acquired its pipeline of radiopharmaceutical candidates. It was the third company Song ...